Cingulate Inc (CING)
NASDAQ:CING
CING Stock Chart & Stats
$5.76
-$0.31(-6.60%)
At close: 4:00 PM EST
$5.76
-$0.31(-6.60%)
Day’s Range― - ―
52-Week Range$3.20 - $11.89
Previous CloseN/A
Volume136.88K
Average Volume (3M)190.99K
Market Cap
$66.98M
Enterprise Value$30.12M
Total Cash (Recent Filing)$10.95M
Total Debt (Recent Filing)$8.79M
Price to Earnings (P/E)―
Beta5.42
Next Earnings
May 13, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding11,628,613
10 Day Avg. Volume270,731
30 Day Avg. Volume190,985
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.40
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$11.00Price Target Upside90.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial RunwayCingulate's combined cash position and access to capital should be sufficient to fund development and commercialization milestones, reducing near-term financing risk.
Market ValidationAcquisition activity in the ADHD sector validates the commercial opportunity for Cingulate's therapy and could increase investor interest in the company's market potential.
Product DifferentiationCTx-1301's triple-release formulation provides full-day symptom coverage and could remove the need for booster doses, potentially improving patient adherence and commercial uptake.
Bears Say
Guidance UncertaintyAbsence of forward guidance from management increases uncertainty about future performance and may heighten stock volatility and investor reluctance.
Operating LossesA reported quarterly net loss and missed earnings per share expectations underline ongoing operating deficits that may pressure the stock until revenue growth is visible.
Regulatory Manufacturing RiskThe FDA's request for additional chemistry, manufacturing and controls information raises the risk of delayed regulatory decisions and could push back the approval timeline.
Cingulate Inc News
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $3.20 and its highest was $11.89 in the past 12 months.
What is Cingulate Inc’s market cap?
Cingulate Inc’s market cap is $66.98M.
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is May 13, 2026 which is in 31 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on Mar 18, 2026. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.632 by -$0.318.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -0.52.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 11,628,613 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.632. Following the earnings report the stock price went down -31.046%.
Which hedge fund is a major shareholder of Cingulate Inc?
Currently, no hedge funds are holding shares in CING
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cingulate Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (90.97% Upside)
$11.00 (90.97% Upside)
Hedge Fund Trend
Decreased
By 97.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $166.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 17.4%
Last 30 Days ▲ 31.9%
Last 30 Days ▲ 31.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.59%
12-Months-Change
Fundamentals
Return on Equity
-602.02%
Trailing 12-Months
Asset Growth
1.40%
Trailing 12-Months
Company Description
Cingulate Inc
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
CING Stock 12 Month Forecast
Average Price Target
$11.00
▲(90.97% Upside)
Technical Analysis
Bio Green Med Solution
―
NanoViricides
―
Enlivex
―
FibroBiologics, Inc.
―
Boundless Bio Inc.
―
Ownership Overview
1.48% Insiders
1.35% Mutual Funds
0.86% Other Institutional Investors
94.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---